fda warning letter glp-1 october 2025 On August 15 2025, the U.S. Food & Drug Administration (FDA) issued a to Platinum Biologics LLC for marketing umbilical‑cord‑derived products including exosome products (“NanoEx” & “Nano Xsomes”) without approval Coalition Urges FDA to Act

If you're tracking progress, consider using more than one metric: weekly averages, waist measurements, and strength numbers tell a fuller story than a single weigh-in

Your employer has a significant say in what medications your plan covers, especially for self-funded plans

Do I need to diet and exercise while taking GLP-1

New indications underwriters cant ignore Fatty liver disease (MASH) Formerly known as NASH, metabolic dysfunction associated steatohepatitis is a form of fatty liver disease associated with significantly increased risks of diabetes, heart failure, kidney disease, cirrhosis, and liver cancer

The strategy that works: Don't appeal based on "my doctor says I need this." Appeal based on plan language

Taking 1 mL working solution as an example, add 100 L DMSO stock solution ( 25.0 mg/mL ) to 400 L PEG300 , and mix evenly